Search

Kymera Therapeutics Inc

Затворен

СекторЗдравеопазване

117.35 3.11

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

111.89

Максимум

117.97

Ключови измерители

By Trading Economics

Приходи

8M

-61M

Продажби

31M

65M

EPS

-0.62

Марж на печалбата

-94.171

Служители

273

EBITDA

6M

-61M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+14.78% upside

Дивиденти

By Acuity

Следващи печалби

3.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

777M

9B

Предишно отваряне

114.24

Предишно затваряне

117.35

Kymera Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.08.2026 г., 20:06 ч. UTC

Kymera Therapeutics Inc shares are higher today, recovering from an earlier pullback amid a mixed market backdrop following a decline in U.S. retail sales.

12.08.2026 г., 20:01 ч. UTC

Kymera Therapeutics Inc shares are trading higher amid increased activity and unusually high market volume, with no specific news identified to explain the movement.

6.08.2026 г., 19:56 ч. UTC

Kymera Therapeutics Inc shares are lower today, trading near the lower end of their one-month range amid broader market dynamics and inflationary concerns.

5.08.2026 г., 20:02 ч. UTC

Social Media
News

Kymera Therapeutics reported a narrower net loss of $61.21 million for Q2 2026, driven by increased collaboration revenue and a price target raise from Stifel to $132.

4.08.2026 г., 20:04 ч. UTC

Correlated Moves

Kymera Therapeutics Inc is rising in Tuesday's session, reflecting bullish sentiment in the biotechnology sector amid a broader market uptrend.

3.08.2026 г., 19:46 ч. UTC

News

Kymera Therapeutics Inc shares are lower amid volatility, following Dimensional Fund Advisors LP's 5% stake reduction and broader market trends in biotechnology.

31.07.2026 г., 20:06 ч. UTC

Correlated Moves

Kymera shares lower amid SPDR S&P Biotech ETF decline.

30.07.2026 г., 19:39 ч. UTC

Kymera Therapeutics Inc shares are higher during Thursday's session, with no specific news identified to explain the price action amid broader market trends.

29.07.2026 г., 19:32 ч. UTC

Macro Event

Kymera Therapeutics shares are higher as the Federal Reserve maintains rates at 3.50%–3.75%. Investors monitor inflation trends and their impact on future policy.

28.07.2026 г., 17:42 ч. UTC

News
Social Media

Shares lower despite Guggenheim's price target increase to $135.

27.07.2026 г., 21:03 ч. UTC

News

Kymera Therapeutics shares are lower in after-market hours following the appointment of Terence Rooney, MD, as Chief Medical Officer, succeeding Jared Gollob, MD.

24.07.2026 г., 18:46 ч. UTC

Kymera Therapeutics Inc. shares are roughly flat as trading fluctuates within a narrow range, reflecting routine activity without specific news.

21.07.2026 г., 19:16 ч. UTC

Kymera Therapeutics Inc is trading higher, supported by broader market strength and optimism in AI stocks, despite a pullback earlier in the session.

20.07.2026 г., 22:16 ч. UTC

Kymera Therapeutics Inc shares are lower in after-market hours. Broader market sentiment is influenced by rising Treasury yields amid interest rate and geopolitical concerns.

Сравнение с други в отрасъла

Ценова промяна

Kymera Therapeutics Inc Прогноза

Ценова цел

By TipRanks

14.78% нагоре

12-месечна прогноза

Среден 131.33 USD  14.78%

Висок 155 USD

Нисък 112 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за Kymera Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

18 ratings

16

Купи

2

Задържане

0

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
help-icon Live chat